Citius Oncology Reports $1.67 Million Revenue in Q2 2026, Faces $26.61 Million Net Loss

Citius Oncology, Inc. reported its financial results for the second quarter of fiscal year 2026, revealing a revenue of $1.67 million for the three months ended March 31, 2026, compared to no revenue in the same period last year. For the six months ended March 31, 2026, the company generated $5.61 million in revenue, marking a significant milestone following the commercial launch of its oncology immunotherapy product, LYMPHIR, in December 2025. Despite this revenue generation, Citius Oncology reported a net loss of $26.61 million for the quarter and $32.14 million for the six-month period, reflecting an increase in operating expenses primarily due to a contract cancellation fee of approximately $19.73 million related to a terminated manufacturing agreement.

The company's total operating expenses surged to $29.95 million for the three months ended March 31, 2026, up from $7.47 million in the prior year, largely driven by increased general and administrative costs. Research and development expenses decreased to $1.08 million from $3.14 million year-over-year, as the previous year's figures included costs associated with pre-license inspection batches. The amortization of in-process research and development began in December 2025, contributing $1.72 million to the operating expenses for the quarter.

Citius Oncology's balance sheet as of March 31, 2026, showed total assets of $100.70 million, slightly down from $100.94 million at the end of the previous fiscal year. The company had cash and cash equivalents of $2.63 million, down from $3.92 million, and a negative working capital of approximately $29.4 million. The company’s liabilities increased to $65.43 million, up from $56.08 million, primarily due to accrued expenses and a license payable. The total stockholders' equity decreased to $35.27 million from $44.87 million, reflecting the ongoing losses.

In terms of strategic developments, Citius Oncology has made significant strides in expanding its market presence. The company reported that 83% of target accounts have added or are actively progressing with LYMPHIR through formulary reviews, and it has secured broad market access with 135 health plans covering 80% of lives. Additionally, the company announced its first shipment of LYMPHIR to Europe, marking a key step in its international expansion efforts. Citius Oncology is also actively engaged in capital raising efforts, having received approximately $11.5 million from warrant exercises and entered into a loan agreement for up to $25 million to support its operations.

Looking ahead, Citius Oncology anticipates continued revenue growth as LYMPHIR gains market acceptance and expands its presence in both the U.S. and international markets. However, the company acknowledges the need for substantial additional financing to support its operations beyond November 2026, raising concerns about its ability to continue as a going concern. The company is exploring various strategic alternatives to maximize shareholder value while managing its financial obligations and operational challenges.